Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Navamedic ASA (OSL:NAVA) (Lysaker, Norway, 26 September 2008) Navamedic ASA has been informed that the preliminary position of the transparency committee in France is to de-reimburse all symptomatic slow acting drugs in osteoarthritis (SYSADOA).
Currently, four products classified as symptomatic slow acting drugs in osteoarthritis are reimbursed in France. These products are used by approximately 1 million patients in France and have a combined turnover of around EUR 200 million. The committee has voted to de-reimburse these products. This will be applied unless the position is changed following the appeal process described below. The position also applies for Glucomed, which is the first new product in this class in France in several years.
All the involved companies are invited to request a meeting with the transparency committee during the next few months, where the companies can appeal the position and present its arguments for continued reimbursement. A final decision will be made following the appeal process. Navamedic will participate in this meeting together with its marketing and distribution partner and argue for reimbursement for Glucomed.
If the preliminary position is sustained, Navamedic and the marketing and distribution partner will consider how to address the large French market.
For further information, please contact:
Øyvind W. Brekke, CEO Navamedic ASA E-mail: oyvind.brekke@navamedic.com Office: +47 67 11 25 40 Mobile: +47 91 19 81 64
